Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073944 · ClinicalTrials.gov registry record · Phase 1
BCX-1777 in Treating Patients With Refractory Cancer
A Phase 1 study of Cancer, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00073944 is a Phase 1 study of Cancer that has completed, run by BioCryst Pharmaceuticals. The trial reports 1 study location across 1 state.
The verdict
NCT00073944, a Phase 1 study of Cancer, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
Conditions Studied
Interventions
- DRUG forodesine hydrochloride
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073944
The ClinicalTrials.gov registry entry for NCT00073944 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which forodesine hydrochloride is the first listed.
NCT00073944 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00073944 about?
NCT00073944 is a clinical study titled "BCX-1777 in Treating Patients With Refractory Cancer". RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
What is the current status of trial NCT00073944?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-04.
What conditions does trial NCT00073944 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00073944?
The interventions under investigation include: forodesine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00073944?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073944 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.